Anabasum

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) gained 10 percent on Thursday in reaction to the company's encouraging update to a phase 2 trial of its autoimmune disease drug called anabasum. Corbus' top-line data from a 22-patient study of anabasum for the treatment of...

Shares of Corbus Pharmaceuticals Holdings Inc (NASDAQ: CRBP) were trading lower by around 10 percent Thursday morning, even though the company reported positive, top-line data from an ongoing clinical trial. Corbus has been exploring its Anabasum (Resunab) therapy in a Phase 2 study for the...